Brand Reference: Farxiga
| Metric | Verified Benchmark | Source |
|---|---|---|
| Dapagliflozin RxNorm Concept ID | 1488564 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $17.8400 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $584.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $38.20 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $46.00 / mo | 17 Zero-PHI Verified Patient Logs |
Reversibly inhibits luminal SGLT2 co-transporters with >1,400-fold selectivity over intestinal SGLT1, promoting insulin-independent renal glucose excretion, afferent arteriolar vasoconstriction, plasma volume offloading, and cardiorenal fibrosis attenuation.
Classified under Proximal Tubular SGLT2 Inhibitor (Rx), Dapagliflozin exhibits a $545.80/month gap between standard U.S. retail cash counters ($584.00) and verified direct-to-patient routing ($38.20) anchored to $17.8400 CMS unit cost.
Pharmacokinetic profiling of Dapagliflozin demonstrates an elimination half-life of 12.9 hours with 78% oral systemic bioavailability; clearance proceeds via converted primarily by ugt1a9 to inactive dapagliflozin 3-o-glucuronide, reaching clinical onset within 2 hours fasting cmax.
Titration schedules for Dapagliflozin (5 mg PO once daily → 10 mg PO once daily) require excluding prior anaphylaxis to dapagliflozin; active dialysis dependence; real-world patient logs highlight increased urination (20% of reports), urinary tract discomfort (9% of reports), volume depletion (8% of reports) alongside a 87.90% Worth-It consensus.
Across 17 verified cash-pay logs, Dapagliflozin achieves a 87.90% Worth-It rating with out-of-pocket spend averaging $46.00/mo versus $584.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 5 mg PO once daily for Dapagliflozin; monthly out-of-pocket dropped to $33.62 compared with $584.00 retail.
Completed 10 weeks on Dapagliflozin (10 mg PO once daily). Zero notable side effects on steady dosing.
Consistent biomarker response on 5 mg PO once daily Dapagliflozin sourced via TeleMed ($44.31/mo cash pay without insurance prior authorization).